Is Regeneron Pharmaceuticals (REGN) A Worthy Investment?

Oakmark Funds, an investment management firm, published its “Oakmark Select Fund” second quarter 2021 investor letter – a copy of which can be seen here.  A return of 7.96% was reported by the fund in the Q2 of 2021, just behind the S&P 500 Index’s 8.6% return for the same period. You can take a look at the fund’s top 5 holdings to have an idea about their top bets for 2021.

In the Q2 2021 investor letter of Oakmark Funds, the fund mentioned Regeneron Pharmaceuticals, Inc....